130 related articles for article (PubMed ID: 14599854)
1. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
3. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE; Rose JW
Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Othman AA; Tran JQ; Tang MT; Dutta S
Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
[TBL] [Abstract][Full Text] [Related]
9. An anti-interleukin-2 receptor drug attenuates T- helper 1 lymphocytes-mediated inflammation in an acute model of endotoxin-induced uveitis.
Mérida S; Sancho-Tello M; Navea A; Almansa I; Muriach M; Bosch-Morell F
PLoS One; 2014; 9(3):e90216. PubMed ID: 24595020
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab therapy for multiple sclerosis.
Bielekova B
Neurotherapeutics; 2013 Jan; 10(1):55-67. PubMed ID: 23055048
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Zhang Y; McClellan M; Efros L; Shi D; Bielekova B; Tang MT; Vexler V; Sheridan JP
Mult Scler; 2014 Feb; 20(2):156-64. PubMed ID: 23846354
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal effects of daclizumab treatment of multiple sclerosis.
Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
18. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Wiendl H; Gross CC
Nat Rev Neurol; 2013 Jul; 9(7):394-404. PubMed ID: 23732529
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab Therapy for Multiple Sclerosis.
Bielekova B
Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 29661806
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
Sampson JH; Schmittling RJ; Archer GE; Congdon KL; Nair SK; Reap EA; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Mitchell DA
PLoS One; 2012; 7(2):e31046. PubMed ID: 22383993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]